Tandem Diabetes Care (NSDQ:TNDM) said today that it enrolled the first patient in an at-home pivotal trial of its t:slim X2 insulin pump combined with the company’s predictive low glucose suspend algorithm. Using DexCom’s G5 mobile continuous glucose monitor and Tandem’s predictive technology, the insulin pump is designed to halt insulin delivery when it predicts low […]
Tandem Diabetes Care
Tandem shares slide after Q2 sales miss
Shares in Tandem Diabetes Care (NSDQ:TNDM) fell yesterday after the medical device maker missed sales expectations but beat EPS estimates on Wall Street with its second quarter results. The San Diego, Calif.-based company posted a loss of -$21.8 million, or -44¢ per share, on sales of $21.3 million for the 3 months ended June 30, for […]
ADA 2017 Roundup: Photo ban causes stir among conference attendees
Many scientific conferences have embraced the technological age, creating hashtags for attendees to share content on Twitter and engage with one another. Some conferences even acknowledge attendees with powerful social media presences by giving them special ribbons and including their Twitter handles on their name badges. But at this year’s meeting of the American Diabetes […]
Artificial pancreas: These companies are racing to make one
Medical device companies are close to achieving the holy grail of diabetes treatment: a combined glucose sensor, control algorithm and insulin infusion device that effectively acts as an “artificial pancreas.” We explain more in the newest video from editors at Drug Delivery Business’s sister publication Medical Design & Outsourcing. (And for a deeper dive, check out […]
Tandem misses on Q1 earnings, beats rev estimates
Shares in Tandem Diabetes (NSDQ:TNDM) fell today after the medical device maker missed earnings expectations on Wall Street with its 1st quarter results, but beat revenue estimates. The San Diego-based company posted losses of -$23.8 million, or -75¢ per share, on sales of $18.9 million for the 3 months ended March 31, for bottom-line loss of -13.9% […]
Tandem Diabetes launches t:connect healthcare portal
Tandem Diabetes Care (NSDQ:TNDM) launched the t:connect HCP Portal for its cloud-based t:connect diabetes management app, which integrates with the company’s touchscreen insulin pumps. Healthcare providers can now upload data from a Tandem pump and blood glucose meter simultaneously, according to Tandem. They can also find patients quickly and set patient-specific ranges to identify data that […]
Tandem Diabetes Care prices $22.5m public offering
Tandem Diabetes Care (NSDQ:TNDM) today announced the pricing details of a $22.5 million underwritten public offering. The company priced 18 million shares of its common stock at $1.25 apiece. Tandem also gave underwriters a 30-day option to buy up to an additional 2.7 million shares of common stock at the public offering price. The offering is expected […]
Tandem looks to raise $50m in public offering; shares fall despite Q4 earnings win
Shares in Tandem Diabetes Care (NSDQ:TNDM) fell today, although the medical device maker met expectations on Wall Street with its 4th quarter results. The San Diego-based company posted losses of -$15.7 million, or -48¢ per share, on sales of $24.8 million for the 3 months ended Dec. 31, for bottom-line loss of -40% on sales loss […]
Tandem claims 1st remote software update for insulin pump
Tandem Diabetes Care (NSDQ:TNDM) said today that it released a software update using the company’s Tandem Device Updater tool for its t:slim insulin pumps purchased before April 2015. It marks the 1st time an insulin pump manufacturer has provided a software update that employs customers’ personal computers. The Mac and PC-compatible tool remotely overhauls Tandem’s insulin pump software, […]
Dexcom surges on Medicare nod for continuous glucose monitors
DexCom (NSDQ:DXCM) said yesterday that the Centers for Medicare & Medicaid classified therapeutic continuous glucose monitors as durable medical equipment under Medicare Part B. The company’s Dexcom G5 Mobile is the only CGM system that falls under this classification, according to San Diego, Calif.-based DexCom, since patients can make treatment decisions using the device. DXCM […]